Small-cell lung cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Barnard, 1926, The nature of the ‘oat-celled sarcoma’ of the mediastinum, J Pathol, 29, 241, 10.1002/path.1700290304
Watson, 1962, Oat cell lung cancer, Cancer, 15, 759, 10.1002/1097-0142(196207/08)15:4<759::AID-CNCR2820150410>3.0.CO;2-6
Chute, 1999, Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress, J Clin Oncol, 17, 1794, 10.1200/JCO.1999.17.6.1794
Tyczynski, 2003, Lung cancer in Europe in 2000: epidemiology, prevention, and early detection, Lancet Oncol, 4, 45, 10.1016/S1470-2045(03)00960-4
Brownson, 1992, Gender and histologic type variations in smoking-related risk of lung cancer, Epidemiology, 3, 61, 10.1097/00001648-199201000-00012
Khuder, 2001, Effect of smoking cessation on major histologic types of lung cancer, Chest, 120, 1577, 10.1378/chest.120.5.1577
Spindel, 1987, Transient elevation of messenger RNA encoding gastrin-releasing peptide, a putative pulmonary growth factor in human fetal lung, J Clin Invest, 80, 1172, 10.1172/JCI113176
Cardona, 1991, Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines, Cancer Res, 51, 5205
Sausville, 1986, Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs, J Biol Chem, 261, 2451, 10.1016/S0021-9258(17)35956-2
Corjay, 1991, Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells, J Biol Chem, 266, 18771, 10.1016/S0021-9258(18)55129-2
Toi-Scott, 1996, Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells, Lung Cancer, 15, 341, 10.1016/0169-5002(95)00597-8
Cuttitta, 1985, Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer, Nature, 316, 823, 10.1038/316823a0
Chaudhry, 1999, Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer, Clin Cancer Res, 5, 3385
Heinrich, 2003, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J Clin Oncol, 21, 4342, 10.1200/JCO.2003.04.190
Hibi, 1991, Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer, Oncogene, 6, 2291
Sekido, 1991, Preferential expression of c-kit protooncogene transcripts in small cell lung cancer, Cancer Res, 51, 2416
Rygaard, 1993, Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts, Br J Cancer, 67, 37, 10.1038/bjc.1993.7
Boldrini, 2004, Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance, Clin Cancer Res, 10, 4101, 10.1158/1078-0432.CCR-03-0664
Wang, 2000, Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571, Oncogene, 19, 3521, 10.1038/sj.onc.1203698
Wolff, 2004, Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer, Clin Cancer Res, 10, 3528, 10.1158/1078-0432.CCR-0957-03
Johnson, 2003, Phase II study of imatinib in patients with small cell lung cancer, Clin Cancer Res, 9, 5880
Dy, 2005, A phase II NCCTG/CALGB trial of imatinib (STI571) in patients with c-kit-expressing relapsed small cell lung cancer (SCLC), Proc Am Clin Soc Oncol, 7048, 10.1200/jco.2005.23.16_suppl.7048
Schmidt, 2004, The role of c-myc in regulation of translation initiation, Oncogene, 23, 3217, 10.1038/sj.onc.1207548
Prins, 1993, The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types, Anticancer Res, 13, 1373
Johnson, 1988, myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines, Cancer Res, 48, 5163
Brennan, 1991, myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens, Cancer Res, 51, 1708
Akie, 2000, A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer, Antisense Nucleic Acid Drug Dev, 10, 243, 10.1089/108729000421420
Johnson, 1986, Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene, J Clin Invest, 78, 525, 10.1172/JCI112604
Lindblad-Toh, 2000, Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays, Nat Biotechnol, 18, 1001, 10.1038/79269
Naylor, 1987, Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer, Nature, 329, 451, 10.1038/329451a0
Hibi, 1992, Three distinct regions involved in 3p deletion in human lung cancer, Oncogene, 7, 445
Pekarsky, 2002, FHIT as tumor suppressor: mechanisms and therapeutic opportunities, Cancer Biol Ther, 1, 232, 10.4161/cbt.73
Rong, 2004, Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G/M arrest, Oncogene, 23, 8216, 10.1038/sj.onc.1207901
Lin, 2000, Unique anti-activator protein-1 activity of retinoic acid receptor beta, Cancer Res, 60, 3271
Liu, 1996, Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells, Mol Cell Biol, 16, 1138, 10.1128/MCB.16.3.1138
Kondo, 2001, Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells, Oncogene, 20, 6258, 10.1038/sj.onc.1204832
Uno, 2004, Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells, Cancer Res, 64, 2969, 10.1158/0008-5472.CAN-03-3702
Sozzi, 1996, The FHIT gene 3p14.2 is abnormal in lung cancer, Cell, 85, 17, 10.1016/S0092-8674(00)81078-8
Burbee, 2001, Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression, J Natl Cancer Inst, 93, 691, 10.1093/jnci/93.9.691
Virmani, 2000, Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas, J Natl Cancer Inst, 92, 1303, 10.1093/jnci/92.16.1303
Siprashvili, 1997, Replacement of Fhit in cancer cells suppresses tumorigenicity, Proc Natl Acad Sci USA, 94, 13771, 10.1073/pnas.94.25.13771
Dammann, 2000, Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3, Nat Genet, 25, 315, 10.1038/77083
Ito, 2004, Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo, Cancer Gene Ther, 11, 733, 10.1038/sj.cgt.7700756
Olivier, 2002, The IARC TP53 database: new online mutation analysis and recommendations to users, Hum Mutat, 19, 607, 10.1002/humu.10081
Kaye, 2002, RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer, Oncogene, 21, 6908, 10.1038/sj.onc.1205834
Cantley, 1999, New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway, Proc Natl Acad Sci USA, 96, 4240, 10.1073/pnas.96.8.4240
Virmani, 1998, Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types, Genes Chromosomes Cancer, 21, 308, 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2
Forgacs, 1998, Mutation analysis of the PTEN/MMAC1 gene in lung cancer, Oncogene, 17, 1557, 10.1038/sj.onc.1202070
Chute, 1985, Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont, Cancer, 56, 2107, 10.1002/1097-0142(19851015)56:8<2107::AID-CNCR2820560837>3.0.CO;2-T
Chin, 2000, Increasing use of bronchoscopic needle aspiration to diagnose small cell lung cancer, Mayo Clin Proc, 75, 796, 10.4065/75.8.796
Delgado, 2000, Small cell carcinoma versus other lung malignancies: diagnosis by fine-needle aspiration cytology, Cancer, 90, 279, 10.1002/1097-0142(20001025)90:5<279::AID-CNCR3>3.0.CO;2-D
Tondini, 1989, Small-cell lung cancer: importance of fiberoptic bronchoscopy in the evaluation of complete remission, Tumori, 75, 266, 10.1177/030089168907500316
Travis, 1999, Epithelial tumours, 25
Field, 2004, Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review, J Natl Cancer Inst, 96, 1105, 10.1093/jnci/djh189
Campling, 1995, Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer, Cancer, 75, 2442, 10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q
Johnson, 1997, A prospective study of patients with lung cancer and hyponatremia of malignancy, Am J Respir Crit Care Med, 156, 1669, 10.1164/ajrccm.156.5.96-10075
George, 1972, Biosynthesis of vasopressin in vitro and ultrastructure of a bronchogenic carcinoma: patient with the syndrome of inappropriate secretion of antidiuretic hormone, J Clin Invest, 51, 141, 10.1172/JCI106784
Gross, 1993, Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium, Cancer Res, 53, 67
Kamoi, 1990, Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus, J Clin Endocrinol Metab, 70, 1385, 10.1210/jcem-70-5-1385
Wong, 2002, Systemic diseases associated with disorders of water homeostasis, Endocrinol Metab Clin North Am, 31, 121, 10.1016/S0889-8529(01)00007-X
Forrest, 1978, Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone, N Engl J Med, 298, 173, 10.1056/NEJM197801262980401
Shepherd, 1992, Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer, J Clin Oncol, 10, 21, 10.1200/JCO.1992.10.1.21
Stewart, 1994, ACTH precursors characterize the ectopic ACTH syndrome, Clin Endocrinol (Oxf), 40, 199, 10.1111/j.1365-2265.1994.tb02468.x
Winquist, 1995, Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production, J Clin Oncol, 13, 157, 10.1200/JCO.1995.13.1.157
Sher, 1989, Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome, Lancet, 2, 640, 10.1016/S0140-6736(89)90893-3
Lambert, 1971, Quantal components of end-plate potentials in the myasthenic syndrome, Ann N Y Acad Sci, 183, 183, 10.1111/j.1749-6632.1971.tb30750.x
Voltz, 1999, P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system, Muscle Nerve, 22, 119, 10.1002/(SICI)1097-4598(199901)22:1<119::AID-MUS19>3.0.CO;2-5
Tim, 1998, Lambert-Eaton myasthenic syndrome (LEMS): clinical and electrodiagnostic features and response to therapy in 59 patients, Ann N Y Acad Sci, 841, 823, 10.1111/j.1749-6632.1998.tb11024.x
Chalk, 1990, Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma, Neurology, 40, 1552, 10.1212/WNL.40.10.1552
McEvoy, 1989, 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome, N Engl J Med, 321, 1567, 10.1056/NEJM198912073212303
Sanders, 2003, Lambert-eaton myasthenic syndrome: diagnosis and treatment, Ann N Y Acad Sci, 998, 500, 10.1196/annals.1254.065
Motomura, 2000, Apheresis treatment in Lambert-Eaton myasthenic syndrome, Ther Apher, 4, 287, 10.1046/j.1526-0968.2000.004004287.x
Zelen, 1973, Keynote address on biostatistics and data retrieval, Cancer Chemother Rep 3, 4, 31
Janne, 2002, Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America, Cancer, 95, 1528, 10.1002/cncr.10841
Argiris, 2001, Staging and clinical prognostic factors for small-cell lung cancer, Cancer J, 7, 437
Jones, 2001, Value and accuracy of cytology in addition to histology in the diagnosis of lung cancer at flexible bronchoscopy, Respir Med, 95, 374, 10.1053/rmed.2001.1051
Hochstenbag, 2000, Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis, J Neurooncol, 48, 243, 10.1023/A:1006427407281
Richardson, 1993, Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs, Arch Intern Med, 153, 329, 10.1001/archinte.1993.00410030043007
Bradley, 2004, Positron emission tomography in limited-stage small-cell lung cancer: a prospective study, J Clin Oncol, 22, 3248, 10.1200/JCO.2004.11.089
Paesmans, 2000, Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years, Cancer, 89, 523, 10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6
Spiegelman, 1989, Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients, J Clin Oncol, 7, 344, 10.1200/JCO.1989.7.3.344
Albain, 1990, Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base, J Clin Oncol, 8, 1563, 10.1200/JCO.1990.8.9.1563
Osterlind, 1986, Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation, Cancer Res, 46, 4189
Wolf, 1991, Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival, Br J Cancer, 63, 986, 10.1038/bjc.1991.215
Turrisi, 1999, Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide, N Engl J Med, 340, 265, 10.1056/NEJM199901283400403
Fox, 1973, Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus: ten-year follow-up, Lancet, 2, 63, 10.1016/S0140-6736(73)93260-1
Mountain, 1978, Clinical biology of small cell carcinoma: relationship to surgical therapy, Semin Oncol, 5, 272
Shepherd, 1991, Surgical treatment for limited small-cell lung cancer: the University of Toronto Lung Oncology Group experience, J Thorac Cardiovasc Surg, 101, 385, 10.1016/S0022-5223(19)36720-0
Rea, 1998, Long term results of surgery and chemotherapy in small cell lung cancer, Eur J Cardiothorac Surg, 14, 398, 10.1016/S1010-7940(98)00203-6
Osterlind, 1986, Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer: a study of 150 operable patients, Eur J Cancer Clin Oncol, 22, 589, 10.1016/0277-5379(86)90048-9
Karrer, 1989, The importance of surgical and multimodality treatment for small cell bronchial carcinoma, J Thorac Cardiovasc Surg, 97, 168, 10.1016/S0022-5223(19)35321-8
Cohen, 1979, Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma, Cancer Treat Rep, 63, 163
Salazar, 1991, Radiation therapy for chest recurrences following induction chemotherapy in small cell lung cancer, Int J Radiat Oncol Biol Phys, 21, 645, 10.1016/0360-3016(91)90682-T
Sundstrom, 2002, Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up, J Clin Oncol, 20, 4665, 10.1200/JCO.2002.12.111
Takada, 2002, Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104, J Clin Oncol, 20, 3054, 10.1200/JCO.2002.12.071
Ihde, 1994, Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer, J Clin Oncol, 12, 2022, 10.1200/JCO.1994.12.10.2022
Murray, 1993, Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer, J Clin Oncol, 11, 336, 10.1200/JCO.1993.11.2.336
Byrne, 1989, Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial, Br J Cancer, 60, 413, 10.1038/bjc.1989.296
Giaccone, 1993, Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial, J Clin Oncol, 11, 1230, 10.1200/JCO.1993.11.7.1230
Sculier, 1996, Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer, J Clin Oncol, 14, 2337, 10.1200/JCO.1996.14.8.2337
Beith, 1996, Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung, Eur J Cancer, 32A, 438, 10.1016/0959-8049(95)00608-7
Pignon, 1992, A meta-analysis of thoracic radiotherapy for small-cell lung cancer, N Engl J Med, 327, 1618, 10.1056/NEJM199212033272302
Jeremic, 1997, Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study, J Clin Oncol, 15, 893, 10.1200/JCO.1997.15.3.893
Auperin, 1999, Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission, N Engl J Med, 341, 476, 10.1056/NEJM199908123410703
Breneman, 1997, Stereotactic radiosurgery for the treatment of brain metastases: results of a single institution series, Cancer, 79, 551, 10.1002/(SICI)1097-0142(19970201)79:3<551::AID-CNCR18>3.0.CO;2-2
Li, 2000, Comparison of three treatment options for single brain metastasis from lung cancer, Int J Cancer, 90, 37, 10.1002/(SICI)1097-0215(20000220)90:1<37::AID-IJC5>3.0.CO;2-7
Noda, 2002, Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer, N Engl J Med, 346, 85, 10.1056/NEJMoa003034
Hanna, 2005, Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC), Proc Am Soc Clin Oncol, 7004, 10.1200/jco.2005.23.16_suppl.lba7004
Eckardt, 2005, Comparable activity with oral topotecan/cisplatin (TC) and IV etoposide/cisplatin (PE) as treatment for chemotherapy-naive patients with extensive disease small cell lung cancer (ED-SCLC): final results of a randomized phase III trial, Proc Am Soc Clin Oncol, 7003, 10.1200/jco.2005.23.16_suppl.7003
Loehrer, 1995, Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study, J Clin Oncol, 13, 2594, 10.1200/JCO.1995.13.10.2594
Pujol, 2001, Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study, J Natl Cancer Inst, 93, 300, 10.1093/jnci/93.4.300
Arriagada, 1993, Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer, N Engl J Med, 329, 1848, 10.1056/NEJM199312163292504
Fetscher, 1997, Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer, Ann Oncol, 8, 57, 10.1023/A:1008209713568
Elias, 1999, Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome, J Clin Oncol, 17, 1175, 10.1200/JCO.1999.17.4.1175
Humblet, 1987, Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study, J Clin Oncol, 5, 1864, 10.1200/JCO.1987.5.12.1864
Slevin, 1989, A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer, J Clin Oncol, 7, 1333, 10.1200/JCO.1989.7.9.1333
Cavalli, 1978, VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules, Cancer Treat Rep, 62, 473
Miller, 1995, Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B, J Clin Oncol, 13, 1871, 10.1200/JCO.1995.13.8.1871
Furuse, 1998, Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer, J Clin Oncol, 16, 2126, 10.1200/JCO.1998.16.6.2126
Murray, 1991, Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer, J Clin Oncol, 9, 1632, 10.1200/JCO.1991.9.9.1632
Sculier, 2001, A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics, Br J Cancer, 85, 1444, 10.1054/bjoc.2001.2114
Steward, 1998, Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients, J Clin Oncol, 16, 642, 10.1200/JCO.1998.16.2.642
Bishop, 1987, Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer, J Clin Oncol, 5, 1574, 10.1200/JCO.1987.5.10.1574
Skarlos, 1994, Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer, Ann Oncol, 5, 601, 10.1093/oxfordjournals.annonc.a058931
Ettinger, 1990, A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group, J Clin Oncol, 8, 230, 10.1200/JCO.1990.8.2.230
Schiller, 2001, Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593, a phase III trial of the Eastern Cooperative Oncology Group, J Clin Oncol, 19, 2114, 10.1200/JCO.2001.19.8.2114
Evans, 1987, Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: a multicenter, randomized clinical trial by the National Cancer Institute of Canada, Ann Intern Med, 107, 451, 10.7326/0003-4819-107-4-451
Fukuoka, 1991, Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer, J Natl Cancer Inst, 83, 855, 10.1093/jnci/83.12.855
Roth, 1992, Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group, J Clin Oncol, 10, 282, 10.1200/JCO.1992.10.2.282
Rigas, 2003, Adjuvant targeted therapy in unresectable lung cancer: the results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI), Lung Cancer, 41, S34, 10.1016/S0169-5002(03)91765-X
Heymach, 2002, Phase II study of the farnesyl transferase inhibitorr (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC), Proc Am Soc Clin Oncol, 21, 319a
Johl, 2005, The proteosome inhibitor PS-341 (Bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): a SWOG (0327) phase II trial, Proc Am Soc Clin Oncol, 7047, 10.1200/jco.2005.23.16_suppl.7047
Pandya, 2005, A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy: a preliminary report, Proc Am Soc Clin Oncol, 7005, 10.1200/jco.2005.23.16_suppl.7005
Arriagada, 1995, Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission, J Natl Cancer Inst, 87, 183, 10.1093/jnci/87.3.183
Gregor, 1997, Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial, Eur J Cancer, 33, 1752, 10.1016/S0959-8049(97)00135-4
Bork, 1991, Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study, J Clin Oncol, 9, 1627, 10.1200/JCO.1991.9.9.1627
Souhami, 1997, Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy, J Natl Cancer Inst, 89, 577, 10.1093/jnci/89.8.577
Girling, 1996, Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial, Lancet, 348, 563, 10.1016/S0140-6736(96)02005-3
Evans, 1995, Oral etoposide and carboplatin: effective therapy for elderly patients with small cell lung cancer, Am J Clin Oncol, 18, 149, 10.1097/00000421-199504000-00011
Matsui, 1998, Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer, Br J Cancer, 77, 1961, 10.1038/bjc.1998.325
Westeel, 1998, New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen, J Clin Oncol, 16, 1940, 10.1200/JCO.1998.16.5.1940
von Pawel, 1999, Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer, J Clin Oncol, 17, 658, 10.1200/JCO.1999.17.2.658
Perez-Soler, 1996, Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan, J Clin Oncol, 14, 2785, 10.1200/JCO.1996.14.10.2785
Ardizzoni, 1997, Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease, J Clin Oncol, 15, 2090, 10.1200/JCO.1997.15.5.2090
Ardizzoni, 2003, European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer, Clin Cancer Res, 9, 143
Masuda, 1998, Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer, J Clin Oncol, 16, 3329, 10.1200/JCO.1998.16.10.3329
Groen, 1999, Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule, J Clin Oncol, 17, 927, 10.1200/JCO.1999.17.3.927
Stephens, 1996, Long-term survival in small cell lung cancer: the case for a standard definition, Lung Cancer, 15, 297, 10.1016/0169-5002(95)00594-3
Lassen, 1995, Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years—an analysis of 1,714 consecutive patients, J Clin Oncol, 13, 1215, 10.1200/JCO.1995.13.5.1215
Tucker, 1997, Second primary cancers related to smoking and treatment of small-cell lung cancer, J Natl Cancer Inst, 89, 1782, 10.1093/jnci/89.23.1782
van der Gaast, 1993, Long term survival of small cell lung cancer patients after chemotherapy, Br J Cancer, 67, 822, 10.1038/bjc.1993.150
Johnson